Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid

Natalizumab exerts impressive therapeutic effects in patients with multiple sclerosis (MS). The proposed main mode of action is reducing transmigration of leukocytes into the CNS, but other immunological effects may also be operative. Cytokines and chemokines are involved in the regulation of inflammatory responses and may reflect the disease process in MS. The objective of this study was to evaluate the effects of natalizumab treatment on cytokine and chemokine profiles systemically and intrathecally in multiple sclerosis. We used luminex to analyse a panel of cytokines (IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, TNF-α, IFN-γ, GM-CSF) and chemokines (CXCL9, CXCL10, CXCL11, CCL17, CCL22) in blood and cerebrospinal fluid (CSF) from 31 patients with relapsing MS before and after one year of natalizumab treatment. There was a marked decline in CSF levels of cytokines and chemokines, thus including pro-inflammatory cytokines (IL-1β, IL-6 and IL-8) as well as chemokines associated with both Th1 (CXCL9, CXCL10, CXCL11) and Th2 (CCL22). Circulating plasma levels of some cytokines (GM-CSF, TNF-α, IL-6 and IL-10) also decreased after one year of treatment. This is the first study to show that natalizumab treatment is associated with a global decline in cytokine and chemokine levels at a protein level. This finding was most pronounced in CSF, in line with the reduced transmigration of cells into CNS, whereas reduction in plasma levels indicates other possible mechanisms of natalizumab treatment.

[1]  M. Khademi,et al.  The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment‐sensitive biomarkers , 2009, European journal of neurology.

[2]  H. Davies,et al.  Expression of Chemokines and Their Receptors by Human Brain Endothelium: Implications for Multiple Sclerosis , 2009, Journal of neuropathology and experimental neurology.

[3]  F. Zipp,et al.  Therapeutic targeting of chemokine signaling in Multiple Sclerosis , 2008, Journal of the Neurological Sciences.

[4]  R. Ransohoff,et al.  Inflammatory Cell Migration into the Central Nervous System: A Few New Twists on an Old Tale , 2007, Brain pathology.

[5]  J. Losy,et al.  Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies , 2007, Acta neurologica Scandinavica.

[6]  J. Bennett,et al.  Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases. , 2007, CNS drug reviews.

[7]  A. Bar-Or,et al.  Natalizumab effects on immune cell responses in multiple sclerosis , 2006, Annals of neurology.

[8]  S. Cepok,et al.  Immune surveillance in multiple sclerosis patients treated with natalizumab , 2006, Annals of neurology.

[9]  Ludwig Kappos,et al.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[10]  P. Calabresi,et al.  Anti-&agr;4 integrin therapy for multiple sclerosis: Mechanisms and rationale , 2005, Neurology.

[11]  F. Sellebjerg,et al.  Cytokines and adhesion molecules in multiple sclerosis patients treated with interferon-beta1b. , 2004, Cytokine.

[12]  M. D. de Bruin‐Weller,et al.  Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell- attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis. , 2004, The Journal of allergy and clinical immunology.

[13]  M. Kvarnström,et al.  Elispot assay detection of cytokine secretion in multiple sclerosis patients treated with interferon-b1a or glatiramer acetate compared with untreated patients , 2003, Multiple sclerosis.

[14]  Shailesh Singh,et al.  IFN-γ-inducible chemokines enhance adaptive immunity and colitis , 2003 .

[15]  I. Romero,et al.  Regulation of chemokine receptor expression in human microglia and astrocytes , 2003, Journal of Neuroimmunology.

[16]  David H. Miller,et al.  A controlled trial of natalizumab for relapsing multiple sclerosis. , 2003, The New England journal of medicine.

[17]  R. Suzuki,et al.  Presence of high contents of thymus and activation-regulated chemokine in platelets and elevated plasma levels of thymus and activation-regulated chemokine and macrophage-derived chemokine in patients with atopic dermatitis. , 2002, The Journal of allergy and clinical immunology.

[18]  Koichiro Nakamura,et al.  Serum macrophage‐derived chemokine (MDC) levels are closely related with the disease activity of atopic dermatitis , 2002, Clinical and experimental immunology.

[19]  A. Compston,et al.  Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.

[20]  R. Bergamaschi,et al.  Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies , 2001, Journal of Neuroimmunology.

[21]  J. Lafitte,et al.  Expression of IFN-gamma-inducible protein; monocyte chemotactic proteins 1, 3, and 4; and eotaxin in TH1- and TH2-mediated lung diseases. , 2001, The Journal of allergy and clinical immunology.

[22]  N. Solvason,et al.  Chemokines in autoimmune diseases , 2000, Immunological reviews.

[23]  T. Olsson,et al.  Reduction of both pro- and anti-inflammatory cytokines after 6 months of interferon beta-1a treatment of multiple sclerosis , 2000, Journal of Neuroimmunology.

[24]  M. Duddy,et al.  Changes in plasma cytokines induced by interferon-β1a treatment in patients with multiple sclerosis , 1999, Journal of Neuroimmunology.

[25]  H. Weiner,et al.  CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Jakob S. Jensen,et al.  Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. , 1999, The Journal of clinical investigation.

[27]  M. Baggiolini.  Chemokines and leukocyte traffic , 1998, Nature.

[28]  J. Ernerudh,et al.  CD4 and CD8 lymphocyte subsets in cerebrospinal fluid and peripheral blood from patients with multiple sclerosis, meningitis and normal controls , 1998, Acta neurologica Scandinavica.

[29]  A. Bar-Or,et al.  Altered CD 4 / CD 8 T-Cell Ratios in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis , 2006 .

[30]  R. Ransohoff,et al.  The expression and function of chemokines involved in CNS inflammation. , 2006, Trends in pharmacological sciences.

[31]  U. Yamashita,et al.  Regulation of macrophage-derived chemokine (MDC, CCL22) production. , 2002, Critical reviews in immunology.